Blog

Kite’s CAR-T cancer therapy shows strong results as company races to win FDA approval – STAT


STAT

Kite's CART cancer therapy shows strong results as company races to win FDA approval
STAT
The treatment involves filtering a patient's blood to remove key immune system soldiers called Tcells, altering them in the lab to contain a gene that targets cancer, and giving them back intravenously. Doctors call it a “living drug” — permanently
Kite Pharma (KITE) Reports Positive Topline Data on Axicabtagene Ciloleucel from First Pivotal CART Trial in StreetInsider.com


Gene therapy to fight a blood cancer succeeds in major studyAtlanta Journal Constitution
Ahead of Q4 Financials, Analysts are Upbeat about Kite Pharma …Economic Calendar

all 21 news articles »

2017-02-28 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.